Brazil’s Anvisa Clears First-Ever Single-Dose Dengue Vaccine Butantan-DV

The move echoes Brazil’s 1937 adoption of the yellow-fever vaccine and the U.S. 1955 Salk polio rollout—moments when a single scientific advance reshaped vector-borne disease control. Unlike the 2017 Dengvaxia debacle in the Philippines that eroded public trust, Butantan-DV is publicly produced, single-shot, and targets naive as well as previously infected groups, potentially avoiding past pitfalls. Strategically, it signals a shift from reactive spraying and hospital care—still evident in Pakistan’s KP or Bangladesh’s record 92,000 cases this year—toward pre-emptive immunization. On a century scale, as climate change pushes Aedes mosquitoes into temperate zones and urban water stress fuels breeding, a thermostable single-dose vaccine could become as routine as measles shots, altering the global geography of dengue rather than merely flattening the next seasonal peak.